But the headline is that CagriSema allowed people to lose 20.4% of their body weight on average—better than Wegovy, but about on par with what people can achieve with Eli Lilly’s Zepbound.

Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial underwhelmed investors, and Novo stock is down almost 20% on the news. However, investors ...

On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of its new GLP-1 candidates, called CagriSema. The name CagriSema is simply an amalgamation of the two primary ...

Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

A researcher in a lab coat working with a microscope, studying a biopharmaceutical drug. Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish ...

The MHRA will continue monitoring the drug’s safety and effectiveness. UBS also noted that CagriSema’s performance now appears more aligned with Amgen’s MariTide. However, due to the ...